Chelsea Therapeutics’ Northera Advisory Review May Turn On Validity Of Combined Clinical Trial Analysis
This article was originally published in The Pink Sheet Daily
Executive Summary
Only one of two pivotal Phase III clinical trials of Chelsea Therapeutics’ Northera (droxidopa) for symptomatic neurogenic orthostatic hypotension showed significant results, but a combined analysis of both trials ascribes major improvement on three separate scores for subjects in the active arm.